Metformin × glycemic control

TrialDiabetes care2013

The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.

Pascale Fouqueray et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 156 people · 2013

No range given

Reported lower glycemic control, no range given

−0.44percentage points

As reported

difference −0.44 %, no interval

One number in the abstract

the abstract, start to end

in A1C with metformin-imeglimin was -0.44% (P < 0.001).

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Glycemic control
−0.44
MetforminOther glucose-loweringGlycemic control

Metformin × glycemic controlhelps?replicated

unlikelylikely
0.840.84 without it

Other glucose-lowering × glycemic controlhelps?mixed

unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

44 papers cite it

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 23160726